Global Formulation Development Service 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI02256045

Publication Date:

February 28, 2025

Pages:

124

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Formulation Development Service market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Formulation Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Formulation Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Formulation Development Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Formulation Development Service players cover Dalton Pharma Services, Recipharm, Aurigene Pharmaceutical Services, Pharma Mo, Ardena, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淔ormulation Development Service Industry Forecast鈥� looks at past sales and reviews total world Formulation Development Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Formulation Development Service sales for 2025 through 2031. With Formulation Development Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Formulation Development Service industry.
This Insight Report provides a comprehensive analysis of the global Formulation Development Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Formulation Development Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Formulation Development Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Formulation Development Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Formulation Development Service.
This report presents a comprehensive overview, market shares, and growth opportunities of Formulation Development Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Sterile Dosage Forms
Non-sterile Dosage Forms
Segmentation by Application:
Pharmaceutical Industry
Health Care Products Industry
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Dalton Pharma Services
Recipharm
Aurigene Pharmaceutical Services
Pharma Mo
Ardena
Intertek
Quay Pharma
Avivia
Metrics Contract Services
Syngene
Kemwell Biopharma
Evonik Industries AG
SGS SA
Coriolis Pharma
Doppel Farmaceutici Srl
Nuvisan
Quotient Sciences
Medpharm
PD Partners

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Formulation Development Service 麻豆原创 Size (2020-2031)
2.1.2 Formulation Development Service 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Formulation Development Service by Country/Region (2020, 2024 & 2031)
2.2 Formulation Development Service Segment by Type
2.2.1 Sterile Dosage Forms
2.2.2 Non-sterile Dosage Forms
2.3 Formulation Development Service 麻豆原创 Size by Type
2.3.1 Formulation Development Service 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Formulation Development Service 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Formulation Development Service Segment by Application
2.4.1 Pharmaceutical Industry
2.4.2 Health Care Products Industry
2.4.3 Others
2.5 Formulation Development Service 麻豆原创 Size by Application
2.5.1 Formulation Development Service 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Formulation Development Service 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Formulation Development Service 麻豆原创 Size by Player
3.1 Formulation Development Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Formulation Development Service Revenue by Player (2020-2025)
3.1.2 Global Formulation Development Service Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Formulation Development Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Formulation Development Service by Region
4.1 Formulation Development Service 麻豆原创 Size by Region (2020-2025)
4.2 Global Formulation Development Service Annual Revenue by Country/Region (2020-2025)
4.3 Americas Formulation Development Service 麻豆原创 Size Growth (2020-2025)
4.4 APAC Formulation Development Service 麻豆原创 Size Growth (2020-2025)
4.5 Europe Formulation Development Service 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Formulation Development Service 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Formulation Development Service 麻豆原创 Size by Country (2020-2025)
5.2 Americas Formulation Development Service 麻豆原创 Size by Type (2020-2025)
5.3 Americas Formulation Development Service 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Formulation Development Service 麻豆原创 Size by Region (2020-2025)
6.2 APAC Formulation Development Service 麻豆原创 Size by Type (2020-2025)
6.3 APAC Formulation Development Service 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Formulation Development Service 麻豆原创 Size by Country (2020-2025)
7.2 Europe Formulation Development Service 麻豆原创 Size by Type (2020-2025)
7.3 Europe Formulation Development Service 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Formulation Development Service by Region (2020-2025)
8.2 Middle East & Africa Formulation Development Service 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Formulation Development Service 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Formulation Development Service 麻豆原创 Forecast
10.1 Global Formulation Development Service Forecast by Region (2026-2031)
10.1.1 Global Formulation Development Service Forecast by Region (2026-2031)
10.1.2 Americas Formulation Development Service Forecast
10.1.3 APAC Formulation Development Service Forecast
10.1.4 Europe Formulation Development Service Forecast
10.1.5 Middle East & Africa Formulation Development Service Forecast
10.2 Americas Formulation Development Service Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Formulation Development Service Forecast
10.2.2 Canada 麻豆原创 Formulation Development Service Forecast
10.2.3 Mexico 麻豆原创 Formulation Development Service Forecast
10.2.4 Brazil 麻豆原创 Formulation Development Service Forecast
10.3 APAC Formulation Development Service Forecast by Region (2026-2031)
10.3.1 China Formulation Development Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Formulation Development Service Forecast
10.3.3 Korea 麻豆原创 Formulation Development Service Forecast
10.3.4 Southeast Asia 麻豆原创 Formulation Development Service Forecast
10.3.5 India 麻豆原创 Formulation Development Service Forecast
10.3.6 Australia 麻豆原创 Formulation Development Service Forecast
10.4 Europe Formulation Development Service Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Formulation Development Service Forecast
10.4.2 France 麻豆原创 Formulation Development Service Forecast
10.4.3 UK 麻豆原创 Formulation Development Service Forecast
10.4.4 Italy 麻豆原创 Formulation Development Service Forecast
10.4.5 Russia 麻豆原创 Formulation Development Service Forecast
10.5 Middle East & Africa Formulation Development Service Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Formulation Development Service Forecast
10.5.2 South Africa 麻豆原创 Formulation Development Service Forecast
10.5.3 Israel 麻豆原创 Formulation Development Service Forecast
10.5.4 Turkey 麻豆原创 Formulation Development Service Forecast
10.6 Global Formulation Development Service Forecast by Type (2026-2031)
10.7 Global Formulation Development Service Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Formulation Development Service Forecast
11 Key Players Analysis
11.1 Dalton Pharma Services
11.1.1 Dalton Pharma Services Company Information
11.1.2 Dalton Pharma Services Formulation Development Service Product Offered
11.1.3 Dalton Pharma Services Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Dalton Pharma Services Main Business Overview
11.1.5 Dalton Pharma Services Latest Developments
11.2 Recipharm
11.2.1 Recipharm Company Information
11.2.2 Recipharm Formulation Development Service Product Offered
11.2.3 Recipharm Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Recipharm Main Business Overview
11.2.5 Recipharm Latest Developments
11.3 Aurigene Pharmaceutical Services
11.3.1 Aurigene Pharmaceutical Services Company Information
11.3.2 Aurigene Pharmaceutical Services Formulation Development Service Product Offered
11.3.3 Aurigene Pharmaceutical Services Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Aurigene Pharmaceutical Services Main Business Overview
11.3.5 Aurigene Pharmaceutical Services Latest Developments
11.4 Pharma Mo
11.4.1 Pharma Mo Company Information
11.4.2 Pharma Mo Formulation Development Service Product Offered
11.4.3 Pharma Mo Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Pharma Mo Main Business Overview
11.4.5 Pharma Mo Latest Developments
11.5 Ardena
11.5.1 Ardena Company Information
11.5.2 Ardena Formulation Development Service Product Offered
11.5.3 Ardena Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Ardena Main Business Overview
11.5.5 Ardena Latest Developments
11.6 Intertek
11.6.1 Intertek Company Information
11.6.2 Intertek Formulation Development Service Product Offered
11.6.3 Intertek Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Intertek Main Business Overview
11.6.5 Intertek Latest Developments
11.7 Quay Pharma
11.7.1 Quay Pharma Company Information
11.7.2 Quay Pharma Formulation Development Service Product Offered
11.7.3 Quay Pharma Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Quay Pharma Main Business Overview
11.7.5 Quay Pharma Latest Developments
11.8 Avivia
11.8.1 Avivia Company Information
11.8.2 Avivia Formulation Development Service Product Offered
11.8.3 Avivia Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Avivia Main Business Overview
11.8.5 Avivia Latest Developments
11.9 Metrics Contract Services
11.9.1 Metrics Contract Services Company Information
11.9.2 Metrics Contract Services Formulation Development Service Product Offered
11.9.3 Metrics Contract Services Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Metrics Contract Services Main Business Overview
11.9.5 Metrics Contract Services Latest Developments
11.10 Syngene
11.10.1 Syngene Company Information
11.10.2 Syngene Formulation Development Service Product Offered
11.10.3 Syngene Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Syngene Main Business Overview
11.10.5 Syngene Latest Developments
11.11 Kemwell Biopharma
11.11.1 Kemwell Biopharma Company Information
11.11.2 Kemwell Biopharma Formulation Development Service Product Offered
11.11.3 Kemwell Biopharma Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Kemwell Biopharma Main Business Overview
11.11.5 Kemwell Biopharma Latest Developments
11.12 Evonik Industries AG
11.12.1 Evonik Industries AG Company Information
11.12.2 Evonik Industries AG Formulation Development Service Product Offered
11.12.3 Evonik Industries AG Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Evonik Industries AG Main Business Overview
11.12.5 Evonik Industries AG Latest Developments
11.13 SGS SA
11.13.1 SGS SA Company Information
11.13.2 SGS SA Formulation Development Service Product Offered
11.13.3 SGS SA Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 SGS SA Main Business Overview
11.13.5 SGS SA Latest Developments
11.14 Coriolis Pharma
11.14.1 Coriolis Pharma Company Information
11.14.2 Coriolis Pharma Formulation Development Service Product Offered
11.14.3 Coriolis Pharma Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Coriolis Pharma Main Business Overview
11.14.5 Coriolis Pharma Latest Developments
11.15 Doppel Farmaceutici Srl
11.15.1 Doppel Farmaceutici Srl Company Information
11.15.2 Doppel Farmaceutici Srl Formulation Development Service Product Offered
11.15.3 Doppel Farmaceutici Srl Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Doppel Farmaceutici Srl Main Business Overview
11.15.5 Doppel Farmaceutici Srl Latest Developments
11.16 Nuvisan
11.16.1 Nuvisan Company Information
11.16.2 Nuvisan Formulation Development Service Product Offered
11.16.3 Nuvisan Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Nuvisan Main Business Overview
11.16.5 Nuvisan Latest Developments
11.17 Quotient Sciences
11.17.1 Quotient Sciences Company Information
11.17.2 Quotient Sciences Formulation Development Service Product Offered
11.17.3 Quotient Sciences Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Quotient Sciences Main Business Overview
11.17.5 Quotient Sciences Latest Developments
11.18 Medpharm
11.18.1 Medpharm Company Information
11.18.2 Medpharm Formulation Development Service Product Offered
11.18.3 Medpharm Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Medpharm Main Business Overview
11.18.5 Medpharm Latest Developments
11.19 PD Partners
11.19.1 PD Partners Company Information
11.19.2 PD Partners Formulation Development Service Product Offered
11.19.3 PD Partners Formulation Development Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 PD Partners Main Business Overview
11.19.5 PD Partners Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.